Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Form 8.1(a) - Pfizer Inc.

11th Nov 2015 13:45

RNS Number : 3810F
J.P. Morgan Securities LLC
11 November 2015
 

Ap9

 

APPENDIX 3 DISCLOSURE FORMS

 

 

 

 

FORM 8.1(a)&(b)(i)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

 

1. KEY INFORMATION

 

Name of person dealing (Note 1)

J.P. Morgan Securities LLC - PCS

Company dealt in

Pfizer Inc.

Class of relevant security to which the dealings being disclosed relate (Note 2)

Common Stock

Date of dealing

10 November 2015

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

355,501 0.01

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

355,501 0.01

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

 

(2) Derivatives (other than options)

 

(3) Options and agreements to purchase/sell

Total

Ap10

 

 

3. DEALINGS (Note 4)

 

(a) Purchases and sales

 

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Buy

 

Sale

1

 

8

33.7900

 

33.7800

 

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

 

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap11

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)  NO

 

Date of disclosure

11 November 2015

Contact name

Tung T Le

Telephone number

0207 742 7272

Name of offeree/offeror with which acting in concert

Allergan plc

Specify category and nature of acting in concert status

Adviser to Allergan plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEPKDDQNBDDBDD

Related Shares:

PFZ.L
FTSE 100 Latest
Value8,680.29
Change47.96